Molecular Insight Pharmaceuticals, Inc.

John Marquis

John W Babich

Craig N Zimmerman

Genliang Lu

Kevin P Maresca

John L Joyal

Shawn Hillier

Jian-cheng Wang

Jian-Cheng Wang

A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject.

Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof

A ligand, a pharmaceutically acceptable salt, tautomer, or ester thereof, may be represented as: In the formula, X is selected from the group consisting of &#x2014;(CH)&#x2014;, &#x2014;(CH)&#x2014;O&#x2014;, &#x2014;(CH)&#x2014;N(R)&#x2014;, &#x2014;(CH)&#x2014;N(R)&#x2014;C(O)&#x2014; and &#x2014;O&#x2014;; Ris hydrogen or (C-C)alkyl; G is &#x2014;(CH(R))&#x2014;R&#x2014;, or &#x2014;(CH)&#x2014;C(O)&#x2014;R; G' is &#x2014;(CH(R))&#x2014;R&#x2014;, or &#x2014;(CH)&#x2014;C(O)&#x2014;R; Ris &#x2014;H, &#x2014;OH, NRR, or &#x2014;COH; Ris &#x2014;H, &#x2014;COOH, or substituted or unsubstituted &#x2014;COO(C-C)alkyl; Rand Rare each independently H, substituted or unsubstituted (C-C)alkyl, or substituted or unsubstituted carboxy(C-C)alkylene; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX

The present invention is directed to CA IX inhibitors that conform to Formula I where the substituents X, A, B, D, E, E' and G are as defined above.  Also described are Pt,Cu,Re,Re andTc metal complexes of Formula I compounds which find use as candidate agents for imaging tumors.

Technetium&#x2014;and rhenium-bis(heteroaryl) complexes and methods of use thereof

Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecu le, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.

Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.

Growing community of inventors

Nashua, NH, United States of America

John Marquis